MX2020012065A - Compuestos de ciclopentano. - Google Patents

Compuestos de ciclopentano.

Info

Publication number
MX2020012065A
MX2020012065A MX2020012065A MX2020012065A MX2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A
Authority
MX
Mexico
Prior art keywords
cyclopentane compounds
cyclopentane
compounds
medicine
processes
Prior art date
Application number
MX2020012065A
Other languages
English (en)
Spanish (es)
Inventor
Grigorios Nikitidis
Xiaolin Zhang
Weitao Pan
Jenny Susanna Marika Lindhagen
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2020012065A publication Critical patent/MX2020012065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2020012065A 2018-05-11 2019-05-09 Compuestos de ciclopentano. MX2020012065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018086503 2018-05-11
PCT/EP2019/061888 WO2019215268A1 (en) 2018-05-11 2019-05-09 Cyclopentane compounds

Publications (1)

Publication Number Publication Date
MX2020012065A true MX2020012065A (es) 2021-02-26

Family

ID=66542241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012065A MX2020012065A (es) 2018-05-11 2019-05-09 Compuestos de ciclopentano.

Country Status (16)

Country Link
US (2) US11274091B2 (enExample)
EP (1) EP3790870B1 (enExample)
JP (1) JP7418354B2 (enExample)
KR (1) KR102806779B1 (enExample)
CN (1) CN112424182B (enExample)
AR (1) AR115382A1 (enExample)
AU (1) AU2019266525B2 (enExample)
BR (1) BR112020023065A2 (enExample)
CA (1) CA3099507A1 (enExample)
DK (1) DK3790870T3 (enExample)
ES (1) ES2944735T3 (enExample)
MX (1) MX2020012065A (enExample)
PT (1) PT3790870T (enExample)
TW (1) TWI830733B (enExample)
UY (1) UY38229A (enExample)
WO (1) WO2019215268A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物
JP7594274B2 (ja) * 2019-10-24 2024-12-04 国立大学法人大阪大学 難聴の予防および/または治療用医薬組成物
WO2025008249A1 (en) 2023-07-06 2025-01-09 Basf Se Triazole compounds for the control of invertebrate pests

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
EP1753740A2 (en) * 2004-05-21 2007-02-21 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
RU2481336C2 (ru) * 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
TW200940542A (en) * 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
PL2370442T3 (pl) * 2008-11-26 2013-08-30 Pfizer 3-Aminocyklopentanokarboksamidy jako modulatory receptora chemokiny
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
EP3010916B1 (en) * 2013-06-21 2017-09-27 Merck Patent GmbH 1,3-diaminocyclopentane carboxamide derivatives
MX2016001134A (es) * 2013-07-29 2016-04-29 Merck Patent Gmbh Derivados 1,3-disustituidos de ciclopentano.
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲(江蘇)醫藥有限公司 環戊烷化合物

Also Published As

Publication number Publication date
US20220194922A1 (en) 2022-06-23
EP3790870B1 (en) 2023-04-19
KR20210018287A (ko) 2021-02-17
TWI830733B (zh) 2024-02-01
UY38229A (es) 2019-11-29
KR102806779B1 (ko) 2025-05-12
CN112424182A (zh) 2021-02-26
US20210070733A1 (en) 2021-03-11
DK3790870T3 (da) 2023-05-08
CA3099507A1 (en) 2019-11-14
JP2021523178A (ja) 2021-09-02
AR115382A1 (es) 2021-01-13
PT3790870T (pt) 2023-05-05
CN112424182B (zh) 2023-05-23
JP7418354B2 (ja) 2024-01-19
AU2019266525A1 (en) 2020-11-26
AU2019266525B2 (en) 2024-06-13
US11274091B2 (en) 2022-03-15
TW202016087A (zh) 2020-05-01
BR112020023065A2 (pt) 2021-02-02
US12378218B2 (en) 2025-08-05
WO2019215268A1 (en) 2019-11-14
ES2944735T3 (es) 2023-06-23
EP3790870A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
PH12017501921A1 (en) Novel compounds
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
MX381417B (es) Inhibidores de glucosidasa.
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX378732B (es) Formas solidas novedosas
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MX373320B (es) Compuestos inhibidores de pde2.
UA117779C2 (uk) Піразини як модулятори gpr6
EP4480577A3 (en) Structured elements and methods of use
IN2014MU00916A (enExample)
PH12020500339A1 (en) Novel compounds
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
IN2014CH00304A (enExample)